Tirzepatide Reduces Major Kidney Events More Than Dulaglutide

Mitigating Renal Decline in Type 2 Diabetes

The clinical management of type 2 diabetes has evolved from a primary focus on glycemic control to a comprehensive strategy aimed at reducing organ-specific complications, particularly chronic kidney disease and heart failure [1, 2, 3]. While sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists have been shown to reduce the risk of end-stage kidney disease (odds ratio 0.88, 95% confidence interval 0.83 to 0.94 for sodium-glucose cotransporter-2 inhibitors), substantial residual risk remains for many patients [1, 4, 5]. Tirzepatide, a dual agonist of both the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors (incretin hormones that stimulate insulin secretion), has demonstrated high efficacy in reducing body weight and hemoglobin A1c compared to selective receptor agonists [6, 7, 8, 9]. Meta-analyses of phase 3 trials indicate that tirzepatide 15 mg can achieve a mean hemoglobin A1c reduction of 1.94% (95% confidence interval -2.02 to -1.87) in patients with uncontrolled diabetes [8, 10]. However, the comparative influence of this dual-receptor signaling on definitive renal outcomes versus established active comparators is still being characterized [11, 12]. A recent exploratory analysis of the SURPASS-CVOT trial now offers fresh insights into the long-term kidney outcomes associated with these incretin-based therapeutic classes, providing clinicians with critical data to guide prescribing decisions for patients with comorbid cardiovascular and renal disease.

Trial Design and High-Risk Population Characteristics

To evaluate these renal outcomes, researchers conducted a pre-specified exploratory analysis of the SURPASS-CVOT trial, a randomized, active comparator-controlled, double-blind study funded by Eli Lilly and Company. Conducted across 640 sites in 30 countries between May 29, 2020, and June 27, 2022, the investigators screened 16,979 participants and randomly assigned 13,299 individuals to treatment groups. After excluding 134 participants assigned in error, the final analysis included 6,586 patients in the tirzepatide group and 6,579 patients in the dulaglutide group. The study focused on a highly vulnerable clinical population, requiring participants to be at least 40 years of age with a diagnosis of type 2 diabetes and established atherosclerotic cardiovascular disease. Clinical inclusion also required a hemoglobin A1c between 7% and 10.5% and a body mass index of 25 kg/m2 or greater. Participants received once-weekly subcutaneous injections of either tirzepatide (titrated up to 15 mg) or the selective glucagon-like peptide-1 receptor agonist dulaglutide (administered at a fixed dose of 1.5 mg). A key component of the analysis was categorizing patients by baseline renal risk to understand how the therapies perform across the disease spectrum. The researchers defined high-risk chronic kidney disease using specific clinical thresholds: an estimated glomerular filtration rate (eGFR, a standard measure of kidney filtration capacity) of 60 mL/min per 1.73 m2 or greater paired with a urine albumin-to-creatinine ratio (UACR, a marker of protein leakage indicating glomerular damage) exceeding 300 mg/g; an eGFR between 45 and less than 60 mL/min per 1.73 m2 with a UACR greater than 30 mg/g; or any eGFR below 45 mL/min per 1.73 m2.

Comparative Efficacy in Renal Protection

The investigators evaluated the long-term renal effects of tirzepatide over a median follow-up period of 4.0 years (interquartile range 3.7 to 4.4). At baseline, the study population exhibited significant renal impairment, underscoring the high-risk nature of the cohort and providing a rigorous environment to test the protective effects of dual incretin agonism. Specifically, 2,928 of 13,004 participants (22.5%) had an eGFR of less than 60 mL/min per 1.73 m2, indicating established chronic kidney disease. Furthermore, 4,142 of 12,954 participants (32.0%) had microalbuminuria (early-stage protein leakage) and 1,491 of 12,954 (11.5%) had macroalbuminuria (severe protein leakage). The primary composite kidney outcome was designed as a strict measure of disease progression, defined as the time to the first occurrence of persistent macroalbuminuria, a persistent reduction in eGFR of 50% or greater, end-stage kidney disease, or death from kidney disease. End-stage kidney disease was defined clinically as an eGFR falling below 15 mL/min per 1.73 m2 or the initiation of chronic kidney replacement therapy. In the overall population, tirzepatide reduced the risk of this primary composite kidney outcome by 23% compared to dulaglutide, with 396 events (6.0%) in the tirzepatide group versus 498 events (7.6%) in the dulaglutide group (hazard ratio 0.77; 95% confidence interval 0.68 to 0.88; p=0.0002). For practicing physicians, this finding suggests that tirzepatide provides superior renal protection beyond the benefits already established by standard glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes and cardiovascular disease.

Divergent Benefits Across Risk Strata

The renal benefits of tirzepatide remained consistent across different levels of baseline kidney function, though the specific clinical drivers of these benefits varied significantly by risk category. In the subgroup of participants with low-to-moderate-risk chronic kidney disease, the primary composite kidney outcome occurred in 195 participants (4.0%) in the tirzepatide group compared to 283 participants (5.6%) in the dulaglutide group (hazard ratio 0.70; 95% confidence interval 0.58 to 0.84; p=0.0001). For these lower-risk patients, the reduction in major kidney events was primarily driven by a lower rate of new-onset persistent macroalbuminuria. This indicates that in earlier stages of renal impairment, dual incretin agonism is highly effective at preventing the progression of glomerular damage and subsequent protein leakage. Conversely, in the population with high-risk chronic kidney disease, tirzepatide demonstrated a significant risk reduction with the primary outcome occurring in 185 participants (12.2%) versus 203 participants (14.5%) in the dulaglutide group (hazard ratio 0.79; 95% confidence interval 0.64 to 0.96; p=0.018). Unlike the lower-risk group, the benefit in high-risk patients was primarily driven by a lower rate of decline in the eGFR. The annual rate of decline in eGFR was significantly lower with tirzepatide than with dulaglutide in the overall population, showing a between-group difference of 0.29 mL/min per 1.73 m2 (95% confidence interval 0.17 to 0.41; p<0.0001). This preservation of filtration capacity was even more pronounced in the high-risk chronic kidney disease subgroup, where the annual eGFR decline difference was 0.93 mL/min per 1.73 m2 (95% confidence interval 0.65 to 1.22; p<0.0001) favoring tirzepatide. While the renal outcomes strongly favored tirzepatide, the study noted a higher incidence of gastrointestinal side effects. Nausea, vomiting, and diarrhea were all more common in those receiving tirzepatide than in those receiving dulaglutide, aligning with the known safety profile of incretin-based therapies. For clinicians, these data provide a clear mandate to weigh transient tolerability factors against the demonstrated long-term renal protection, particularly the slowed loss of filtration capacity in patients already at high risk for progressing to dialysis or requiring transplantation.

References

1. Shi Q, Nong K, Vandvik PO, et al. Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. BMJ. 2023. doi:10.1136/bmj-2022-074068

2. Drake T, Landsteiner A, Langsetmo L, et al. Newer Pharmacologic Treatments in Adults With Type 2 Diabetes: A Systematic Review and Network Meta-analysis for the American College of Physicians. Annals of Internal Medicine. 2024. doi:10.7326/m23-1490

3. Zhang J, Guan X, Kong M, Xia M, Yu Y, Zhang C. GLP-1RAs and tirzepatide may reduce heart failure risk in obese but not in non-obese patients with cardiovascular or renal disease: A systematic review and meta-analysis.. Metabolism: clinical and experimental. 2026. doi:10.1016/j.metabol.2025.156433

4. Bray JJH, Foster‐Davies H, Salem A, et al. Glucagon‐like peptide‐1 receptor agonists improve biomarkers of inflammation and oxidative stress: A systematic review and meta‐analysis of randomised controlled trials. Diabetes Obesity and Metabolism. 2021. doi:10.1111/dom.14399

5. Galli M, Benenati S, Simeone B, et al. GLP-1 RAs reduce mortality and cardiovascular events across the spectrum of treated patients: a systematic review and meta-analysis. European Heart Journal. 2025. doi:10.1093/eurheartj/ehaf784.4322

6. Karagiannis T, Malandris K, Avgerinos I, et al. Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials. Diabetologia. 2024. doi:10.1007/s00125-024-06144-1

7. Liu L, Shi H, Xie M, Sun Y, Nahata MC. The Efficacy and Safety of Tirzepatide in Patients with Diabetes and/or Obesity: Systematic Review and Meta-Analysis of Randomized Clinical Trials.. Pharmaceuticals (Basel, Switzerland). 2025. doi:10.3390/ph18050668

8. Bhagavathula AS, Vidyasagar K, Tesfaye W. Efficacy and Safety of Tirzepatide in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Phase II/III Trials.. Pharmaceuticals (Basel, Switzerland). 2021. doi:10.3390/ph14100991

9. Yang X, Yin S, Yu Y, et al. Is tirzepatide 15 mg the preferred treatment strategy for type 2 diabetes? A meta-analysis and trial-sequence-analysis.. European review for medical and pharmacological sciences. 2023. doi:10.26355/eurrev_202308_33290

10. Khan Z, Naeem MO, Khan SK, et al. Comparing Efficacy and Safety of Different Doses of Tirzepatide for the Treatment of Type 2 Diabetes Mellitus: A Meta-Analysis of Randomized Controlled Trials.. Cureus. 2023. doi:10.7759/cureus.44314

11. Liu L, Chen J, Zhang X, et al. The relation between tirzepatide and adverse cardiovascular events or renal adverse events: a meta-analysis based on randomized controlled trials. Diabetology & Metabolic Syndrome. 2025. doi:10.1186/s13098-025-02064-1

12. Zoungas S, D'Alessio D, Pavo I, et al. A comparison of the effects of tirzepatide and dulaglutide on major kidney events in people with type 2 diabetes: pre-specified exploratory analyses of the SURPASS-CVOT trial.. The lancet. Diabetes & endocrinology. 2026. doi:10.1016/S2213-8587(26)00032-X